TLTian-Tian Liu

Tian-Tian Liu

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Tian-Tian Liu has a total of 153 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • ID2 secures cDC1 specification by antagonizing E proteins at a pleiotropic Zeb2 enhancer

    by Feiya Ou, Tian-Tian Liu, Siling Du, Jing Chen, Magdalena Kraft, Giri Nam, Bishan Bhattarai, Hyeyoon Shin, Alyssa R. Koch, Theresa L. Murphy, et al.


  • Two differentiation pathways generate large peritoneal macrophages with one replenishing mesothelial border macrophages

    by Jichang Han, Alexandre Gallerand, Rachel L. Mintz, Jing Chen, Feiya Ou, Shuai Gao, Daniel D. Lee, Mandy M. Chan, Michael T. Harmon, Xue Lin, et al.

    Peritoneal cavity fluid and mesothelial surfaces host distinct resident macrophage populations, among which include the well-described Gata6 + large cavity macrophages (LCMs) in peritoneal fluid. Here, we reveal that LCMs arise from two separable differentiation pathways. In the quantitatively minor pathway, monocytes gave rise to LYVE1 + LCMs but few Gata6 + LCMs. This pathway did not require the transcription factor Gata6 but was severely impaired in mice bearing three mutations in the −165 kb Zeb2 enhancer ( Zeb2 TM ) with impaired monocyte development. The second, dominant pathway supported Gata6-dependent LCMs and was intact in Zeb2 TM mice, even when turnover was enforced by irradiation, and was supported by adoptive transfer of a specialized LCM intermediate expressing Gata6 before the residency marker TIMD4. Functionally, the quantitatively minor LCM pathway distinctly surveilled the mesothelium, replenishing mesothelial border macrophages upon encountering an open niche. Thus, beyond embryonic versus adult hematopoietic paradigms, LCMs with overlapping and distinct phenotypes arise from two pathways linked to divergent fates.

  • Open Access

    ID2 secures cDC1 specification by antagonizing E proteins at a pleiotropic Zeb2 enhancer

    by Kenneth Murphy, Feiya Ou, Tiantian Liu, Siling Du, Jing Chen, Alyssa Koch, Magdalena Kraft, Theresa Murphy

    The transcriptional regulator ID2 is required for type 1 classical dendritic cell (cDC1) specification, yet the mechanism has remained obscure. We previously identified the Zeb2 -165-kb enhancer as key to normal hematopoiesis, controlled by competing CEBP and NFIL3 inputs during myeloid dendritic cell divergence. Here, we uncover an unprecedented role for E proteins in myelopoiesis and demonstrate that ID2 promotes cDC1 development by antagonizing E protein activity at E-boxes within the Zeb2 enhancer. Deleting these E-boxes abolishes lymphoid B cell and plasmacytoid dendritic cell (pDC) development while skewing myelopoiesis toward cDC1s. Remarkably, E-box deletion rescues cDC1 development in Id2-deficient mice. These findings support a two-step model in which NFIL3 transiently represses Zeb2, followed by ID2-mediated inhibition of E proteins to stabilize cDC1 fate specification. Further, this work defines a paradigm of “site-specific pleiotropy,” wherein distinct transcription factor motifs–E-boxes and CEBP sites–within a single enhancer direct diverse cell fates.

  • Combined Flt3L and CD40 agonism restores dendritic cell–driven T cell immunity in pancreatic cancer

    by Graham D. Hogg, Alyssa G. Weinstein, Natalie L. Kingston, Xiuting Liu, Olivia M. Dres, Liang-I Kang, Varintra E. Lander, Yu-Lan Kao, Faiz Ahmad, Brett L. Knolhoff, et al.

    T cell–directed immunotherapies have largely failed to slow progression of pancreatic ductal adenocarcinoma (PDAC) because of poor tumor antigenicity and an immunosuppressive tumor microenvironment. We hypothesized that conventional dendritic cell (cDC) suppression in PDAC may further impair tumor immunity. We found that low tissue expression of Fms-like tyrosine kinase 3 ligand (Flt3L) partially underlies cDC deficits. Treatment with systemic Flt3L and CD40 agonists restored cDC number and function in murine models and clinical trial samples from patients with PDAC. CD40 agonism alone did not fully activate cDCs; however, when combined with Flt3L, dual therapy triggered a cDC-driven type I immune response characterized by T cell infiltration, interleukin-12 production, and reciprocal interferon-γ (IFN-γ) responses. In mice, cDC1s were responsible for CD8 + T cell expansion, and in turn, T cell–derived IFN-γ enhanced cDC1 survival. Nevertheless, Flt3L and CD40 agonism increased regulatory T cells through the activation of cDC2s, dampening immunity. These findings advocate further exploration of DC-centered approaches to enhance antitumor immunity in PDAC.


  • Open Access

    cDC1s Promote Atherosclerosis via Local Immunity and Are Targetable for Therapy

    by Miguel Galán, Laura Fernández-Méndez, Vanessa Núñez, Marcos Femenía-Muiña, Pau Figuera-Belmonte, Elena Moya-Ruiz, Sarai Martínez-Cano, Elena Hernández-García, Manuel Rodrigo-Tapias, Ana Rodríguez-Ronchel, et al.

    BACKGROUND: Atherosclerosis is characterized by immune cell accumulation in the arterial wall and adaptive CD4 + Th1 immunity contributes to atherosclerosis development. However, how conventional dendritic cells (cDCs) orchestrate this adaptive response remains controversial. This study unveils strategies for the gain and loss of function of cDCs to decipher their role in atherosclerosis induction in relation to adaptive T-cell immunity. METHODS: We tested atherosclerosis in Ldlr −/− mice fed a high-cholesterol diet (HCD). Expansion of cDCs in vivo was achieved by overexpression of FLT3L (Fms-like tyrosine kinase 3 ligand), while the effect of ablation of conventional type 1 dendritic cells (cDC1s) in atherosclerosis was analyzed by grafting bone marrow from different mouse models of cDC1 depletion, including Xcr1 Cre−DTA and Irf8 Δ32 mice, into lethally irradiated Ldlr −/− recipients before HCD. CD3 + T-cell subsets were analyzed using flow cytometry or scRNA-seq. Nanoparticles loaded with dexamethasone and decorated with anti-CLEC9A antibody to target cDC1s were tested for immunotherapy. RESULTS: Expansion of dendritic cells in Ldlr − / − mice fed HCD for 8 weeks led to increased atherosclerotic lesion, which was prevented when Ldlr − / − mice were grafted before dendritic cell expansion with Xcr1 Cre−DTA cDC1-depleted bone marrow compared with controls. Consistently, even in the absence of dendritic cell expansion, cDC1 deficiency prevented HCD-induced atherosclerosis. The scRNA-seq analysis of aortic CD3 + T cells in this experimental approach showed a local reduction in CD4 + Th1 and CD8 + IFN (interferon)-γ + T cells in the absence of cDC1s compared with control mice. Mechanistically, stimulator of IFN genes in cDC1s was required for the proatherogenic function of cDC1s. As a potential cDC1-targeted immunotherapy for atherosclerosis, we generated lipid nanoparticles decorated with an anti-CLEC9A antibody to specifically target cDC1s. When loaded with the immunosuppressive drug dexamethasone, these nanoparticles promoted a reduction of the atherosclerotic lesion in Ldlr − / − mice fed HCD, correlating with decreased CD4 + Th1 and CD8 + IFN-γ + T cells in the spleen. These immunosuppressive nanoparticles, however, did not impair antiviral response. CONCLUSIONS: Using state-of-the-art strategies, our results establish that cDC1s have a proatherogenic role in atherosclerosis by boosting CD4 + and CD8 + T-cell immunity and propose that cDC1s can be targeted with an immunosuppressive drug to decrease atherosclerosis progression.


  • Shared pathway of WDFY4-dependent cross-presentation of immune complexes by cDC1 and cDC2

    by Suin Jo, Ray A. Ohara, Derek J. Theisen, Sunkyung Kim, Tiantian Liu, Christopher B. Bullock, Michelle He, Feiya Ou, Jing Chen, Sytse J. Piersma, et al.

    Priming CD8+ T cells against tumors or viral pathogens results largely from cross-presentation of exogenous antigens by type 1 conventional dendritic cells (cDC1s). Although monocyte-derived DCs and cDC2s can cross-present in vitro, their physiological relevance remains unclear. Here, we used genetic models to evaluate the role of cDC subsets in presentation of cell-associated and immune complex antigens to CD4+ and CD8+ T cells in vivo. For cell-associated antigens, cDC1s were necessary and sufficient to prime both CD4+ and CD8+ T cells. In contrast, for immune complex antigens, either cDC1 or cDC2, but not monocyte-derived DCs, could carry out cross-presentation to CD8+ T cells. Mice lacking cDC1 and vaccinated with immune complexes could cross-prime CD8+ T cells that were sufficient to mediate tumor rejection. Notably, this cross-presentation mediated by cDC2 was also WDFY4 dependent, similar to cross-presentation of cell-associated antigens by cDC1. These results demonstrate a previously unrecognized activity of WDFY4 in cDC2s and suggest a cross-presentation pathway shared by cDC subsets.


  • Optimization of the Irf8 +32-kb enhancer disrupts dendritic cell lineage segregation

    by Feiya Ou, Tian-Tian Liu, Pritesh Desai, Stephen T. Ferris, Sunkyung Kim, Haolin Shen, Ray A. Ohara, Suin Jo, Jing Chen, J. Luke Postoak, et al.

    Autoactivation of lineage-determining transcription factors mediates bistable expression, generating distinct cell phenotypes essential for complex body plans. Classical type 1 dendritic cell (cDC1) and type 2 dendritic cell (cDC2) subsets provide nonredundant functions for defense against distinct immune challenges. Interferon regulatory factor 8 (IRF8), the cDC1 lineage-determining transcription factor, undergoes autoactivation in cDC1 progenitors to establish cDC1 identity, yet its expression is downregulated during cDC2 differentiation by an unknown mechanism. This study reveals that the Irf8 +32-kb enhancer, responsible for IRF8 autoactivation, is naturally suboptimized with low-affinity IRF8 binding sites. Introducing multiple high-affinity IRF8 sites into the Irf8 +32-kb enhancer causes a gain-of-function effect, leading to erroneous IRF8 autoactivation in specified cDC2 progenitors, redirecting them toward cDC1 and a novel hybrid DC subset with mixed-lineage phenotypes. Further, this also causes a loss-of-function effect, reducing Irf8 expression in cDC1s. These developmental alterations critically impair both cDC1-dependent and cDC2-dependent arms of immunity. Collectively, our findings underscore the significance of enhancer suboptimization in the developmental segregation of cDCs required for normal immune function.


  • Top Cited Papers
    Open Access

    Neoantigen-specific cytotoxic Tr1 CD4 T cells suppress cancer immunotherapy

    by Hussein Sultan, Yoshiko Takeuchi, Jeffrey P. Ward, Naveen Sharma, Tian-Tian Liu, Vladimir Sukhov, Maria Firulyova, Yuang Song, Samuel Ameh, Simone Brioschi, et al.

    CD4+ T cells can either enhance or inhibit tumour immunity. Although regulatory T cells have long been known to impede antitumour responses1–5, other CD4+ T cells have recently been implicated in inhibiting this response6,7. Yet, the nature and function of the latter remain unclear. Here, using vaccines containing MHC class I (MHC-I) neoantigens (neoAgs) and different doses of tumour-derived MHC-II neoAgs, we discovered that whereas the inclusion of vaccines with low doses of MHC-II-restricted peptides (LDVax) promoted tumour rejection, vaccines containing high doses of the same MHC-II neoAgs (HDVax) inhibited rejection. Characterization of the inhibitory cells induced by HDVax identified them as type 1 regulatory T (Tr1) cells expressing IL-10, granzyme B, perforin, CCL5 and LILRB4. Tumour-specific Tr1 cells suppressed tumour rejection induced by anti-PD1, LDVax or adoptively transferred tumour-specific effector T cells. Mechanistically, HDVax-induced Tr1 cells selectively killed MHC-II tumour antigen-presenting type 1 conventional dendritic cells (cDC1s), leading to low numbers of cDC1s in tumours. We then documented modalities to overcome this inhibition, specifically via anti-LILRB4 blockade, using a CD8-directed IL-2 mutein, or targeted loss of cDC2/monocytes. Collectively, these data show that cytotoxic Tr1 cells, which maintain peripheral tolerance, also inhibit antitumour responses and thereby function to impede immune control of cancer.


  • Open Access

    Transcription factor C/EBPα is required for the development of Ly6C hi monocytes but not Ly6C lo monocytes

    by Sunkyung Kim, Jing Chen, Feiya Ou, Tian-Tian Liu, Suin Jo, William E. Gillanders, Theresa L. Murphy, Kenneth M. Murphy

    Monocytes comprise two major subsets, Ly6C hi classical monocytes and Ly6C lo nonclassical monocytes. Notch2 signaling in Ly6C hi monocytes triggers transition to Ly6C lo monocytes, which require Nr4a1 , Bcl6 , Irf2 , and Cebpb . By comparison, less is known about transcriptional requirements for Ly6C hi monocytes. We find transcription factor CCAAT/enhancer-binding protein alpha (C/EBPα) is highly expressed in Ly6C hi monocytes, but down-regulated in Ly6C lo monocytes. A few previous studies described the requirement of C/EBPα in the development of neutrophils and eosinophils. However, the role of C/EBPα for in vivo monocyte development has not been understood. We deleted the Cebpa +37 kb enhancer in mice, eliminating hematopoietic expression of C/EBPα, reproducing the expected neutrophil defect. Surprisingly, we also found a severe and selective loss of Ly6C hi monocytes, while preserving Ly6C lo monocytes. We find that BM progenitors from Cebpa +37 −/− mice rapidly progress through the monocyte progenitor stage to develop directly into Ly6C lo monocytes even in the absence of Notch2 signaling. These results identify a previously unrecognized role for C/EBPα in maintaining Ly6C hi monocyte identity.


  • Open Access

    Ethyl acetate extract of Terminalia chebula alleviates DSS-induced ulcerative colitis in C57BL/6 mice

    by Wan-Rong Dong, Yao-Yao Li, Tian-Tian Liu, Gao Zhou, Yu-Xin Chen

    Background: The Chinese pharmacopeia records Terminalia chebula as effective in treating prolonged diarrhea and dysentery, blood in the stool, and prolapse. Modern pharmacological research proves it has multiple pharmacological benefits, including antioxidant, anti-inflammatory, analgesic, hepatoprotective, neuroprotective, and other properties.Objectives: This study aims to clarify the role of Terminalia chebula’s ethyl acetate extract (TCEA) on ulcerative colitis (UC) induced by dextran sodium sulfate (DSS) in mice, as well as explore the potential mechanism of action.Materials and methods: The variation of different extracts of T. chebula was detected using the HPLC technique, and the main components in TCEA were identified. DSS was used to establish a mouse model to mimic the physiological state of UC in humans; the alleviating effect of TCEA and positive control 5-ASA on UC mice were evaluated by gavage treatment. Disease progression was assessed by monitoring the mouse’s weight change and disease activity index (DAI). The changes in colon tissue were estimated by measuring colon length, HE, and AB-PAS staining and detecting oxidative stress parameters. The results draw from Western blot and real-time PCR showed the TLR4/MyD88/NF-κB pathway may involve in the anti-inflammatory activity of TCEA. Furthermore, the gut flora sequencing technique was employed to monitor the differentiation of intestinal microbiota of mice induced by DSS and TCEA treatment.Results: TCEA significantly lowered DAI scores and inhibited the weight loss and colonic shortening induced by DSS. The colon histomorphology and oxidative stress levels were enhanced after TCEA treatment compared with DSS induced UC group. TCEA attenuated the inflammatory response by regulating TLR4/MyD88/NF-κB pathway activation. Intestinal flora sequencing showed that DSS and TCEA greatly impacted mice’s composition and diversity of intestinal microorganisms. But TCEA increased the abundance of Bacteroidetes and decreased the abundance of Firmicutes and Proteobacteria compared with the DSS group, which contributed a lot to returning the intestinal flora to a balanced state.Conclusion: This study confirms the alleviating effect of TCEA on UC and provides new ideas for developing TCEA into a new drug to treat UC.